Clinical Trials Logo

Dermatitis clinical trials

View clinical trials related to Dermatitis.

Filter by:

NCT ID: NCT05042258 Not yet recruiting - Atopic Dermatitis Clinical Trials

Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

Start date: June 2024
Phase: Phase 4
Study type: Interventional

Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old

NCT ID: NCT04895423 Not yet recruiting - Atopic Dermatitis Clinical Trials

Evaluation of the Effectiveness and Safety of Immunosuppressive and Biological Therapy of Atopic Dermatitis in Childhood

Start date: November 25, 2021
Phase: Phase 4
Study type: Interventional

This comparative study analyzes the efficacy and safety of treatment of children from 6 years of age suffering from moderate to severe atopic dermatitis using an inhibitor of IL4, IL13 and classical immunosuppressants.

NCT ID: NCT04890197 Not yet recruiting - Breast Cancer Clinical Trials

Tahini and Dermatitis in Breast Cancer

Start date: May 8, 2021
Phase: N/A
Study type: Interventional

This study aimed to investigate the effect of tahini on acute radiation dermatitis in breast cancer (BC) patients undergoing radiotherapy (RT). 50 eligible BC patients will randomly assign to consume tahini 48 gr per day during and 1 week after RT or with no intervention (control group). The radiation dermatitis will be assessed weekly according to the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/EORTC) scales.

NCT ID: NCT04890184 Not yet recruiting - Breast Cancer Clinical Trials

Grape Juice and Dermatitis in Breast Cancer

Start date: May 8, 2021
Phase: N/A
Study type: Interventional

This study aimed to investigate the effect of grape juice on acute radiation dermatitis in breast cancer (BC) patients undergoing radiotherapy (RT). 50 eligible BC patients will randomly assign to consume 100 gr of grape juice per day during and 1 week after RT or with no intervention (control group). The radiation dermatitis will be assessed weekly according to the Radiation Therapy Oncology Group/ European Organization for Research and Treatment of Cancer (RTOG/EORTC) scales.

NCT ID: NCT04888234 Not yet recruiting - Clinical trials for Radiation Dermatitis

Evaluation the Effectiveness of Ru-Yi-Jin-Huang Powder for the Radiation-induced Dermatitis.

Start date: May 8, 2021
Phase: Phase 2
Study type: Interventional

Radiation-induced dermatitis is the most common complication of radiotherapy for cancer treatment. However, there is no satisfactory management to deal with the problem. Ru-Yi-Jin-Huang Powder is one of most common topical TCM drug to treat skin diseases but lack of evidence to support efficacy. The aim of this trial is to evaluate the effectiveness of Ru-Yi-Jin-Huang Powder for radiation-induced dermatitis.

NCT ID: NCT04853823 Not yet recruiting - Contact Dermatitis Clinical Trials

A Safety, Tolerability, and Dermal Reactogenicity Study of PDC-APB

Start date: November 1, 2021
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, single ascending dose study to assess the safety and tolerability of PDC-APB by intramuscular (IM) injection compared to placebo.

NCT ID: NCT04815148 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

MH004 Topical Cream in Healthy Adult Volunteers and Participants With Atopic Dermatitis or Rheumatoid Arthritis

Start date: April 1, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase Ia/Ib Study of MH004 in Healthy Adult Volunteers, participants with Mild to Moderate Atopic Dermatitis and participants with Mild to Moderate Rheumatoid Arthritis.

NCT ID: NCT04730024 Not yet recruiting - Atopic Dermatitis Clinical Trials

Long-term Follow-up Study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj

Start date: March 27, 2022
Phase:
Study type: Observational

A multi-center, open, long-term follow-up study to Evaluate the Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD inj. for Moderate to Severe Chronic Atopic Dermatitis: 5-year Results from the K0104 Extension Study

NCT ID: NCT04686955 Not yet recruiting - Atopic Dermatitis Clinical Trials

The Efficacy of Patients With Moderate to Severe Atopic Dermatitis Treated With Chinese Herbal Medicine

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

Conduct a clinical trial of integration of Chinese and Western medicine to evaluate whether the association of traditional Chinese medicine therapy has a remission effect on atopic dermatitis, and to explore the remission of lesions after an association of Chinese herbal medicine, and the correlation of syndrome differentiation types before and after treatment with Chinese and Western medicine, with a view to better understand the efficacy of atopic dermatitis in the treatment of the same disease in Traditional Chinese Medicine, and provide another option for patients with atopic dermatitis.

NCT ID: NCT04681300 Not yet recruiting - Atopic Dermatitis Clinical Trials

Transcriptomic Landscape of T Lymphocytes of Atopic Dermatitis, Atopic Prurigo Nodularis (of Besnier) and Non-atopic Prurigo Nodularis (of Hyde) Using Single Cell RNA-sequencing

PRURISEQ
Start date: February 2021
Phase:
Study type: Observational

Prurigo nodularis (PN) is a skin condition characterized by symmetrically distributed widespread, pruritic nodules that occurs in patients with chronic pruritus. There are 2 subtypes of PN depending on the association with an atopic dermatitis (AD) : atopic PN (Besnier) and non-atopic PN (Hyde). There are no approved therapies, and treatment options currently used have limited efficacy and their long-term use carries the risk of potential severe toxic effects. The mechanisms triggering PN are still unknown. However, recent findings suggest a major role for the Th2 inflammatory pathway. Beyond advancing the basic understanding of PN pathophysiology, our study might also pave the way for developing novel Th2-targeted therapeutic strategies for PN and AD. The primary objective of this study is to characterize the transcriptional profile of the T lymphocytes isolated from skin samples from patients with PN. This study will allow a gain a deeper understanding of the pathophysiologic mechanism of PN, a better classification of its subtypes, as well as their physiopathologic link with AD. Moreover, it will help shape new effective and safe therapeutic approaches in these diseases which are important for optimal therapeutic management.